Requires treatment with a strong cytochrome P CYPA/ inhibitor
Unable to discontinue use of a strong CYPA inhibitor
Subjects who require therapy with a strong CYPA inhibitor prior to enrollment to this study
The use of strong CYPA inhibitor (with the exception of ketoconazole).
Received a strong cytochrome P (CYP) A inhibitor or inducer within  days prior to the first dose of ibrutinib, OR subjects who require continuous treatment with a strong cytochrome P CYPA inhibitor or inducer
Subjects who received a strong cytochrome P  A (CYPA) inhibitor within  days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYPA inhibitor
Subjects who received a strong cytochrome P (CYP) A inhibitor within  days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYPA inhibitor
Subjects who received a strong cytochrome P  A (CYPA) inhibitor within  days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYPA inhibitor
Subjects who received a strong cytochrome P (CYP) A inhibitor within  days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYP  A inhibitor
Patients who received a strong cytochrome P (CYP) A inhibitor within  days prior to the first dose of ibrutinib or patients who require continuous treatment with a strong CYPA inhibitor with the exception of voriconazole, which will be specifically studied in this protocol
Chronic treatment (i.e. > days) with a strong Cytochrome P (CYPA) inhibitor which cannot be terminated prior to the first dose of ibrutinib.
Patients who received a strong cytochrome P (CYP) A inhibitor within  days prior to the first dose of ibrutinib or patients who require continuous treatment with a strong CYPA inhibitor
Concomitant treatment with strong cytochrome P A/cytochrome P A (CYPA/) inhibitor
Subjects who received a strong cytochrome P family  subfamily A (CYPA) inhibitor within  days prior to the first dose of study drug, or patients who require continuous treatment with a strong CYPA inhibitor are not eligible
Use of a strong CYPA inhibitor within three elimination half-lives of the inhibitor prior to the start of study treatment.
Patients who received a strong cytochrome P (CYP) A inhibitor within  days prior to the first dose of ibrutinib or patients who require continuous treatment with a strong CYPA inhibitor
Concurrent use of a strong CYPA inhibitor. Subjects who have received a strong CYPA inhibitor prior to entering the study must have discontinued therapy for at least  half lives of the prohibited medication.
Requirement for medication with strong CYPA inhibitor
